✨ Free AI Report
Revolution Medicines, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Revolution Medicines, Inc.
Company Research

Revolution Medicines, Inc.: Business Overview, Financials & Competitive Analysis

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, with a pipeline comprising RAS(ON) inhibitors designed to suppress diverse onc...

Analyst-debate audio for Revolution Medicines, Inc.

AskCyborg analysts argue the bull and bear cases for Revolution Medicines, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Specialized RAS-oncology company with late-stage lead asset, FDA priority designation, and significant market opportunity if...

Read the full analyst-debate transcript →
Industry Precision Oncology / Targeted Therapeutics
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Revolution Medicines, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Revolution Medicines, Inc. Overview

Pro stress-test →

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, with a pipeline comprising RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company represents a high-stakes precision oncology play focused on addressing one of oncology's most prevalent and difficult-to-treat driver mutations.

Strategic Profile

Pro stress-test →

The company's lead drug, Daraxonrasib (RMC-6236), is now in global Phase 3 trials and recently secured a Commissioner's National Priority Voucher from the FDA in October 2025. Revolution Medicines is differentiated by its proprietary RAS(ON) inhibitor platform targeting previously undruggable RAS mutations, positioning it as a potential first-to-market player in a large oncology opportunity.

Competitive Landscape

Pro stress-test →

Revolution Medicines competes in the precision oncology and RAS-targeted therapy space against larger pharmaceutical companies and specialized biotech firms developing RAS inhibitors. Key competitors include Amgen, Mirati Therapeutics (acquired by Takeda), and emerging competitors in the RAS mutation space. Revolution's differentiation lies in its multi-selective RAS(ON) platform targeting difficult-to-drug RAS variants.

Industry Context

Revolution Medicines, Inc. operates in Precision Oncology / Targeted Therapeutics.

Key facts

Founded: 2014 · Headquarters: Redwood City, California · Employees: 809 · Market cap: $13.7B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Revolution Medicines, Inc..

  • Lead candidate Daraxonrasib (RMC-6236) secured FDA Commissioner's National Priority Voucher in October 2025
  • Portfolio includes multiple RAS(ON) selective inhibitors (G12C, G12D, G12V, Q61H, G13C) targeting different RAS mutations
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025FDA Commissioner's National Priority Voucher awarded to Daraxonrasib (RMC-6236)
  • 2025Global Phase 3 trial enrollment ongoing for lead RAS(ON) inhibitor candidate
Get alerted when Revolution Medicines, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SotorasibFDA-approved RAS G12C inhibitor for KRAS-mutant cancers→AdagrasibRAS G12C inhibitor in development→AZD6738RAS pathway inhibitor development programs→

Compare Revolution Medicines, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Revolution Medicines, Inc. operates in Precision Oncology / Targeted Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Oncology / Targeted Therapeutics research →
NEW · MCP server

Ask your AI assistant about Revolution Medicines, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Revolution Medicines, Inc. and its top competitor on Cyborg Score”
“What did Revolution Medicines, Inc. do this quarter?”
“Is Revolution Medicines, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Revolution Medicines, Inc. do?+
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, with a pipeline comprising RAS(ON) inhibitors designed to suppress diverse onc...
What is Revolution Medicines, Inc.'s Cyborg Score?+
Revolution Medicines, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Revolution Medicines, Inc.'s main competitors?+
Named competitors include Sotorasib, Adagrasib, AZD6738. The full competitive landscape is in the AskCyborg report.
How can I get the full Revolution Medicines, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Revolution Medicines, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Revolution Medicines, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Precision Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Tyra Biosciences, Inc.7Erasca, Inc.6Acrivon Therapeutics, Inc.5Personalis, Inc.4PMV Pharmaceuticals, Inc.